Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979749 | 0.90 | PDE5A (0.70) | PDE5A | |
| SCHEMBL4979753 | 0.90 | PDE5A (0.70) | PDE5A | |
| SCHEMBL4980108 | 0.89 | PDE5A (0.76) | PDE5A | |
| SCHEMBL4975373 | 0.86 | PDE5A (0.80) | PDE5A | |
| SCHEMBL4976297 | 0.86 | PDE5A (0.54) | PDE5A | |
| SCHEMBL4976358 | 0.86 | PDE5A (0.54) | PDE5A | |
| Avanafil SCHEMBL118799 | 0.84 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL30335524 | 0.84 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL16377474 | 0.84 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL29372265 | 0.84 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| CN-1657523-A | Cyclic compounds | TANABE SEIYAKU CO (JP) | 2005-08-24 | — | — | CN | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| CN-1440393-A | cyclic compound | TANABE SEIYAKU CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | PDE5A 2/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | PDE5A 3/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.